WallStSmart

Akebia Ther (AKBA)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 7365% more annual revenue ($17.35B vs $232.40M). TEVA leads profitability with a 9.0% profit margin vs -8.8%. TEVA earns a higher WallStSmart Score of 66/100 (B-).

AKBA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -5.33

TEVA

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 6.3Quality: 4.0
Piotroski: 6/9Altman Z: 0.28

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AKBA0 strengths · Avg: 0/10

No standout strengths identified

TEVA2 strengths · Avg: 9.0/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

PEG RatioValuation
0.858/10

Growing faster than its price suggests

Areas to Watch

AKBA4 concerns · Avg: 3.5/10
Price/BookValuation
9.4x4/10

Trading at 9.4x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$273.62M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TEVA4 concerns · Avg: 3.0/10
P/E RatioValuation
25.8x4/10

Moderate valuation

Revenue GrowthGrowth
2.3%4/10

2.3% revenue growth

Free Cash FlowQuality
$-208.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.282/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AKBA

AKBA has a balanced fundamental profile.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.

Bear Case : AKBA

The primary concerns for AKBA are Price/Book, EPS Growth, Market Cap.

Bear Case : TEVA

The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.

Key Dynamics to Monitor

AKBA profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.

TEVA carries more volatility with a beta of 0.85 — expect wider price swings.

TEVA is growing revenue faster at 2.3% — sustainability is the question.

AKBA generates stronger free cash flow (-21M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (66/100 vs 21/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Akebia Ther

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?